NASDAQ · OKYO
OKYO Pharma Limited
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
Loading market information…
OTC · OCEL · USD
Stock price, earnings
Quote as of Mar 4, 2024, 08:14 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Organicell Regenerative Medicine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Organicell Regenerative Medicine, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
$0.16-$0.03 (-15.36%)
TPCO Holding Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.81% below the high.
$0.01-$0.04 (-76.0%)
Antisense Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 84.0% below the high.
$0.98$0.00 (0.0%)
American Hemp Ventures, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.82% below the high.
CA$0.11+CA$0.01 (+10.0%)
Rapid Dose Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 42.11% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
$3.21-$0.10 (-3.02%)
Kadimastem Ltd’s quoted price sits in the lower half of its reported 52-week range, 64.61% below the high.
£0.06-£0.00 (-0.17%)
OptiBiotix Health Plc’s quoted price sits in the lower half of its reported 52-week range, 35.67% below the high.
